Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Merck KGaA Discontinues Phase III Lung Cancer Trial of Bintrafusp Alfa

Merck KGaA Discontinues Phase III Lung Cancer Trial of Bintrafusp Alfa

Jan 21, 2021
|
staff reporter

NEW YORK – Merck KGaA on Wednesday said it will stop the Phase III [email protected] Lung 037 trial, within which it was exploring the activity of its investigational bifunctional immunotherapy, bintrafusp alfa, in stage IV non-small lung cancer patients with high PD-L1 expression.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Drug Discovery & Development

  1. Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

  2. After Setbacks, Innate Pharma on Track to Advance NK Cell-based Immunotherapy Pipeline

    Premium

  3. Epizyme Exploring Tazverik Combinations in Basket Trials

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.